MWE Advises Innate Pharma

McDermott’s Paris office worked to negotiate the agreement by which Innate Pharma SA secured from Novo Nordisk A/S the full rights to exclusively develop and market the anti-C5aR antibody, a new therapeutic approach in immuno-oncology.